A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative int...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Sauter, Craig S., Matasar, Matthew J., Schoder, Heiko, Devlin, Sean M., Drullinsky, Pamela, Gerecitano, John, Kumar, Anita, Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., Zelenetz, Andrew D., McCall, Susan J., Miller, Shoshana T., Courtien, Amanda I., Younes, Anas, Moskowitz, Craig H.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909762/
https://ncbi.nlm.nih.gov/pubmed/29386196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-802561
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky